CVKD — Cadrenal Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Cadrenal Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0.033 | 8.4 | 10 | 4.01 |
| Net Total Receivables | — | — | 0.038 | 0.005 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 0.728 | 8.49 | 10.1 | 4.32 |
| Net Property, Plant And Equipment | 0.045 | 0.023 | 0.007 | 0.005 |
| Other Long Term Assets | ||||
| Total Assets | 0.778 | 8.52 | 10.1 | 4.33 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 1.33 | 0.827 | 2.68 | 1.59 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 6.33 | 0.827 | 2.68 | 1.59 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | -5.55 | 7.69 | 7.44 | 2.74 |
| Total Liabilities & Shareholders' Equity | 0.778 | 8.52 | 10.1 | 4.33 |
| Total Common Shares Outstanding |